- Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase1
- In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept1
- Patient safety is of paramount …
A Breakthrough for CML and Cancer Treatment
In May 2001 – exactly 20 years ago – Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a watershed moment in drug discovery, transforming the treatment landscape for chronic …
- EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization
- The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3
- Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 – DARPin® antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 …
Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes (MDS). Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs1.
- MDS, a group of rare and often underdiagnosed blood cancers, is characterized by a dysfunctional immune system and leukemic stem cell proliferation2-4.
- Despite treatment with HMAs – the last treatment innovation in higher-risk (HR) MDS over …
Who would have thought that an ancient Chinese herbal remedy would one day become the panacea for malaria? Sweet wormwood (Artemisia annua) was indeed used in traditional Chinese medicine for more than 2 000 …
- Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
- New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
- Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as first line monotherapy in …
- Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
- Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
- Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network
Basel, May 18, 2021 — …
- Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999
- With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe1
- Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance
The digital press …
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
- Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
- Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
- Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network
Basel, May 18, 2021 — Sandoz, a Novartis …
- Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
- Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wait until 2029 for availability of biosimilar Erelzi
- Sandoz remains committed to pioneering access for patients and contributing to more …